Registration Strip Icon for monitor Surveillez plusieurs cotations en temps réel des principales bourses, telles que Euronext Paris, NASDAQ, NYSE, AMEX, Bovespa et plus encore.

BGNE

BeiGene (BGNE)

BeiGene Ltd
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:BGNE
DateHeureSourceTitreSymboleSociété
15/06/202418h05Business WireBeiGene présentera à l’EHA2024 de nouvelles données sur l’étude SEQUOIA évaluant la bithérapie BRUKINSA® plus vénétoclax dans le traitement de première intention de patients atteints de LLC/PLL à haut risqueNASDAQ:BGNEBeiGene Ltd
15/06/202415h42Business WireEHA2024: BeiGene präsentiert neue Daten der SEQUOIA-Studie zu BRUKINSA® plus Venetoclax für die Erstlinienbehandlung von Hochrisiko-CLL/SLLNASDAQ:BGNEBeiGene Ltd
14/06/202412h00Business WireBeiGene to Present New Data from SEQUOIA Study Evaluating BRUKINSA® plus Venetoclax in High-Risk First-Line CLL/SLL at EHA2024NASDAQ:BGNEBeiGene Ltd
14/06/202401h41Business WireBeiGene and NewBridge Pharmaceuticals FZ LLC Mutually Agree to Conclude BRUKINSA® (Zanubrutinib) Partnership in the Middle East and Africa (MENA) RegionNASDAQ:BGNEBeiGene Ltd
07/06/202423h05Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:BGNEBeiGene Ltd
05/06/202423h23Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:BGNEBeiGene Ltd
05/06/202422h35Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:BGNEBeiGene Ltd
04/06/202412h01Business WireBeiGene to Present at the Goldman Sachs 45th Annual Global Healthcare ConferenceNASDAQ:BGNEBeiGene Ltd
28/05/202414h00GlobeNewswire Inc.BriaCell Announces Clinical Supply Agreement with BeiGene for Bria-OTS™ First in Human StudyNASDAQ:BGNEBeiGene Ltd
24/05/202412h00Business WireBRUKINSA® Data at ASCO Underscore Differentiated Clinical Profile for Treatment of CLL and SLLNASDAQ:BGNEBeiGene Ltd
16/05/202400h10Business WireEHA2024: BeiGene präsentiert neues Hämatologie-Portfolio und Pipeline-DatenNASDAQ:BGNEBeiGene Ltd
15/05/202423h50Business WireBeiGene présente de nouvelles données de portefeuille et de pipeline d'hématologie à l'EHA2024NASDAQ:BGNEBeiGene Ltd
14/05/202422h01Business WireBeiGene Highlights New Hematology Portfolio and Pipeline Data at EHA2024NASDAQ:BGNEBeiGene Ltd
09/05/202421h03Business WireBeiGene meldet Finanzergebnisse für das erste Quartal 2024 und aktuelle GeschäftsentwicklungenNASDAQ:BGNEBeiGene Ltd
09/05/202415h38Business Wireベイジーン、2024年第1四半期決算および事業に関する最新情報を発表NASDAQ:BGNEBeiGene Ltd
09/05/202403h02Business WireBeiGene公布2024年第一季財務業績和最新業務情況NASDAQ:BGNEBeiGene Ltd
09/05/202401h03Business WireBeiGene présente ses résultats financiers du premier trimestre 2024 et ses dernières nouvelles commercialesNASDAQ:BGNEBeiGene Ltd
08/05/202412h00Business WireBeiGene Reports First Quarter 2024 Financial Results and Business UpdatesNASDAQ:BGNEBeiGene Ltd
26/04/202416h34Business WireBeiGene Demonstrates Global Progress in 2023 Responsible Business & Sustainability ReportNASDAQ:BGNEBeiGene Ltd
25/04/202413h11Business WireGlobaler Onkologie-Innovator BeiGene präsentiert auf der ASCO-Jahrestagung 2024 neue Daten aus dem gesamten Portfolio für Hämatologie und solide TumoreNASDAQ:BGNEBeiGene Ltd
25/04/202413h10Business WireBeiGene, innovateur mondial en oncologie, présente de nouvelles données sur l’ensemble de son portefeuille en hématologie et en tumeurs solides lors de la réunion annuelle de l’ASCO 2024NASDAQ:BGNEBeiGene Ltd
24/04/202422h01Business WireGlobal Oncology Innovator BeiGene Highlights New Data across Hematology and Solid Tumor Portfolio at 2024 ASCO Annual MeetingNASDAQ:BGNEBeiGene Ltd
24/04/202401h31Business WireBeiGene erhält von der EU-Kommission die Zulassung für Tislelizumab zur Behandlung von nicht kleinzelligem LungenkrebsNASDAQ:BGNEBeiGene Ltd
24/04/202401h31Business WireBeiGene reçoit l’approbation de la Commission européenne pour le tislelizumab dans le traitement du cancer du poumon non à petites cellulesNASDAQ:BGNEBeiGene Ltd
23/04/202412h00Business WireBeiGene Receives European Commission Approval for Tislelizumab as Treatment for Non-Small Cell Lung CancerNASDAQ:BGNEBeiGene Ltd
16/03/202416h18Business WireBeiGene、化学療法後の進行性または転移性食道扁平上皮癌の治療のためのTEVIMBRA®のFDA承認取得NASDAQ:BGNEBeiGene Ltd
15/03/202422h13Business Wire百濟神州喜獲FDA批准,TEVIMBRA®將用於晚期或轉移性食管鱗狀細胞癌在化療後的治療NASDAQ:BGNEBeiGene Ltd
15/03/202421h02Business WireBeiGene reçoit l'approbation de la FDA pour TEVIMBRA® dans le traitement du carcinome épidermoïde de l’œsophage avancé ou métastatique après une chimiothérapieNASDAQ:BGNEBeiGene Ltd
15/03/202407h06Business WireBeiGene erhält FDA-Zulassung für TEVIMBRA ® zur Behandlung des fortgeschrittenen oder metastasierten Plattenepithelkarzinoms der Speiseröhre nach vorheriger ChemotherapieNASDAQ:BGNEBeiGene Ltd
14/03/202421h28Business WireBeiGene Receives FDA Approval for TEVIMBRA® for the Treatment of Advanced or Metastatic Esophageal Squamous Cell Carcinoma After Prior ChemotherapyNASDAQ:BGNEBeiGene Ltd
 Showing the most relevant articles for your search:NASDAQ:BGNE